Update on momelotinib for myelofibrosis
Abdulraheem Yacoub, MD, University of Kansas Medical Center, Kansas City, MO, updates us on the clinical use of momelotinib, a…
Abdulraheem Yacoub, MD, University of Kansas Medical Center, Kansas City, MO, updates us on the clinical use of momelotinib, a…
Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, shares his excitement for the upcoming 10th World Congress on Controversies in Multiple Myeloma (COMy), which is…
Bruno Paiva, PhD, University of Navarra, Pamplona, Spain, discusses the clinical significance of measurable residual disease (MRD) in patients with relapsed/refractory (R/R) multiple myeloma (MM)…
Bruno Paiva, PhD, University of Navarra, Pamplona, Spain, discusses the clinical significance of measurable residual disease (MRD) in patients with relapsed/refractory (R/R) multiple myeloma (MM)…
Florent Malard, MD, PhD, Saint-Antoine Hospital and Sorbonne University, Paris, France, introduces the PHOEBUS study (NCT05762211), a Phase IIb trial investigating the use of MaaT003,…
Thomas Fox, MbChB, MD, PhD, University College London Hospitals NHS Foundation Trust, London, UK, discusses an individualized approach to assessing potential risks of bone marrow…
Alex Rampotas, MD, University College London, London, UK, summarizes a talk on the role of donor lymphocyte infusion (DLI) in the post-allogenic stem cell transplant…
RĂ©my DulĂ©ry, MD, PhD, Saint-Antoine Hospital, Paris, France, outlines the main side effects associated with post-transplant cyclophosphamide (PTCy) as prophylaxis for graft-versus-host disease (GvHD) following…
Shahram Kordasti, MSc, MD, PhD, King’s College London, London, UK, shares his thoughts on the potential therapeutic capacity of immune checkpoint inhibitors (ICIs) in patients…
The Video Journal of Hematological Oncology (VJHemOnc) is a global, open-access video journal, dedicated to providing trusted and up-to-date medical information in order to improve…
Curtis Lachowiez, MD, Oregon Health & Science University, Portland, OR, discusses promising combination approaches for overcoming venetoclax resistance in acute myeloid leukemia (AML). He mentions…